Table 2 Clinical characteristics stratified by TS, as assessed by initial breast biopsy IHC using HR and HER2 status, of 1048 BOM patients with TS available
From: Characterization of bone only metastasis patients with respect to tumor subtypes
Characteristic | HR+/ HER2− | HR+/HER2+ | HR−/ HER2− | HR−/ HER2+ | Total | p-value (4) |
|---|---|---|---|---|---|---|
Median age at breast cancer diagnosis (years) | 50.61 | 46.46 | 52.71 | 49.14 | 50.03 | 0.0074 |
(Minimum, maximum) | (23, 88) | (20, 83) | (27, 84) | (28, 70) | (20, 88) | |
Race/ethnicity n (%) | ||||||
White, non-Hispanic | 626 (76.34) | 80 (67.23) | 50 (65.79) | 14 (42.42) | 770 (73.47) | 0.0004 |
Black, non-Hispanic | 75 (9.15) | 13 (10.92) | 9 (11.84) | 10 (30.30) | 107 (10.21) | |
Hispanic | 89 (10.85) | 16 (13.45) | 13 (17.11) | 7 (21.21) | 125 (11.93) | |
Asian/Pacific Islander | 19 (2.32) | 7 (5.88) | 4 (5.26) | 2 (6.06) | 32 (3.05) | |
Other | 11 (1.34) | 3 (2.52) | 0 (0.00) | 0 (0.00) | 14 (1.34) | |
Bone metastasis location n (%) | ||||||
Appendicular | 93 (11.41) | 10 (8.47) | 8 (10.53) | 3 (9.38) | 114 (10.95) | 0.1882 |
Axial | 261 (32.02) | 52 (44.07) | 29 (38.16) | 14 (43.75) | 356 (34.20) | |
Both axial and appendicular | 461 (56.56) | 56 (47.46) | 39 (51.32) | 15 (46.88) | 571 (54.85) | |
Number of bone metastases n (%) | ||||||
Single | 153 (18.82) | 23 (19.49) | 15 (20.00) | 8 (24.24) | 199 (19.15) | 0.884 |
Multiple | 660 (81.18) | 95 (80.51) | 60 (80.00) | 25 (75.76) | 840 (80.85) | |
Type of bone metastasis at time of BOM diagnosis (1) n (%) | ||||||
Blastic/Sclerotic | 148 (30.33) | 18 (29.03) | 17 (39.53) | 9 (52.94) | 192 (31.48) | 0.3101 |
Lytic | 249 (51.02) | 30 (48.39) | 17 (39.53) | 7 (41.18) | 303 (49.67) | |
Mixed | 91 (18.65) | 14 (22.58) | 9 (20.93) | 1 (5.88) | 115 (18.85) | |
Neoadjuvant chemotherapy n (%) | ||||||
No | 640 (78.05) | 94 (78.99) | 61 (80.26) | 28 (84.85) | 823 (78.53) | 0.7905 |
Yes | 180 (21.95) | 25 (21.01) | 15 (19.74) | 5 (15.15) | 225 (21.47) | |
Adjuvant chemotherapy n (%) | ||||||
No | 518 (63.17) | 67 (56.30) | 40 (52.63) | 20 (60.61) | 645 (61.55) | 0.1822 |
Yes | 302 (36.83) | 52 (43.70) | 36 (47.37) | 13 (39.39) | 403 (38.45) | |
Adjuvant hormonal therapy n (%) | ||||||
No | 419 (51.10) | 75 (63.03) | 68 (89.47) | 32 (96.97) | 594 (56.68) | <0.0001 |
Yes | 401 (48.90) | 44 (36.97) | 8 (10.53) | 1 (3.03) | 454 (43.32) | |
Bisphosphonate therapy after diagnosis of bone metastasis (2) n (%) | ||||||
No | 51 (7.04) | 10 (9.71) | 8 (14.04) | 2 (7.14) | 71 (7.79) | 0.2405 |
Yes | 673 (92.96) | 93 (90.29) | 49 (85.96) | 26 (92.86) | 841 (92.21) | |
Clinical stage at time of breast cancer diagnosis (3) n (%) | ||||||
Stage I | 48 (9.04) | 3 (3.66) | 4 (8.70) | 1 (4.00) | 56 (8.19) | 0.4535 |
Stage II | 130 (24.48) | 22 (26.83) | 12 (26.09) | 8 (32.00) | 172 (25.15) | |
Stage III | 96 (18.08) | 12 (14.63) | 10 (21.74) | 1 (4.00) | 119 (17.40) | |
Stage IV | 257 (48.40) | 45 (54.88) | 20 (43.48) | 15 (60.00) | 337 (49.27) | |
Bone metastases within 4 months of breast cancer diagnosis n (%) | ||||||
No | 529 (64.51) | 67 (56.30) | 53 (69.74) | 17 (51.52) | 666 (63.55) | 0.096 |
Yes | 291 (35.49) | 52 (43.70) | 23 (30.26) | 16 (48.48) | 382 (36.45) | |
